Alvotech delivered robust Q2 2025 results, highlighted by growth across biosimilar products and global expansion. The company generated $173.2 million in revenue and $32 million in net income. Product launches and cost management contributed to improved profitability and cash performance.

Alvotech reported a substantial increase in total revenues to $132.8 million in Q1 2025, up 260% from the previous year, and achieved a positive adjusted EBITDA of $20.5 million, a significant improvement from a negative $38.4 million in 2023. The company also raised its full-year guidance for top-line revenue and adjusted EBITDA.

Alvotech reported record financial results for full year 2024, with total revenues reaching $492 million, a 427% increase over the prior year, and product revenues reaching $273 million, a 462% increase. The company achieved positive Adjusted EBITDA of $108.3 million, a significant improvement from a negative $291 million in 2023. Three new proposed biosimilars were submitted in major global markets in 2024, with all applications subsequently accepted by regulatory authorities.